PODCAST · business
Biotech Catch-up
by Harry Yoo
The Biotech Catch-Up is a weekly podcast that breaks down the biggest biotech and biopharma news for investors in clear, accessible language. Each episode explains what happened, why it matters, and what to watch next. Hosted by Dr. Yoo, a neuroscientist with experience in biotech equity research, corporate strategy, and investor relations, the show is designed especially for retail investors who want to better understand the science and business behind biotech without getting lost in technical jargon.
Episodes
-
Ep 3. Oct 10, 2026
Welcome to Biotech Catch-Up. I'm Harry. This week, we break down five major biotech and pharma stories from October 5 to October 9, 2026. 1. AbbVie & Genmab — Major Phase 3 win in blood cancer AbbVie and Genmab reported positive Phase 3 results for epcoritamab combined with R-CHOP in newly...
-
Ep 2. Oct 3, 2026
Welcome to Biotech Catch-up. I’m Harry. This week, we break down five major biotech and pharma stories from September 28 to October 2, 2026. 1. Novartis & Abogen — A major mRNA deal Novartis signed a licensing and option agreement with China-based Abogen Biosciences, including $575 million…
more -
Ep 1. Sep 26, 2026
Welcome to Biotech Catch-up. I’m Harry. This episode covers five major biotech news stories from September 21–25, 2026. 1. Viking reported that patients maintained much of their earlier weight loss on less frequent injections during a 12-week period. The next question is whether that result lasts...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
The Biotech Catch-Up is a weekly podcast that breaks down the biggest biotech and biopharma news for investors in clear, accessible language. Each episode explains what happened, why it matters, and what to watch next. Hosted by Dr. Yoo, a neuroscientist with experience in biotech equity research, corporate strategy, and investor relations, the show is designed especially for retail investors who want to better understand the science and business behind biotech without getting lost in technical jargon.
HOSTED BY
Harry Yoo
Loading similar podcasts...